The global fiducial markers market is set to reach US$ 138.7 million in 2022 and further expand at a CAGR of 7.9% to end up at a market valuation of US$ 295.6 million by 2032.
Pure gold markers lead the race and are anticipated to contribute more than 55% share of the global market during the forecast period (2022-2032).
Prominent fiducial marker manufacturers are Eckert & Ziegler BEBIG, Innovative Oncology Solutions, Boston Scientific, IBA Dosimetry, Best Medical International, Inc., IZI Medical Products, Carbon Medical Technologies, CIVCO, alphaXRT, Nanovi A/S, and Stellar Medical.
Most companies producing fiducial markers are working towards expanding their product portfolios. However, the most significant approach towards increasing the customer pool is through the marketing of the product through online portals. Making the product available on online channels is also expected to drive the growth of the market.
- In 2020, Innovative Oncology Solutions launched its new range of fiducial markers – SBRT Immobilization, Supine Breast & Thorax Positioning, and others.
- In 2020, CIVCO launched its new extensive range of fiducial markers – such as Solstice™ MR SRS Immobilization System, Monarch™ Vac-Lok™ Options, and others.
Fact.MR has provided detailed information about the price points of key manufacturers of fiducial markers positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.
Segmentation of Fiducial Marker Industry Research
By Product Type :
- Polymer-based Markers
- Metal-based Markers
- Pure Gold Markers
- Liquid-based Markers
By Modality :
- Photon Therapy
- Proton Therapy
By Disease Site :
- Head & Neck
- Cervix or Other Gynaecologic Organs
By End User :
- Cancer Research Institutes
- Radiotherapy Centers
By Region :
- North America
- Latin America
- East Asia
- South Asia & ASEAN